Why Everyone's Getting Their Mitochondria Tested

LA Times Studios may earn commission from purchases made through our links.
Mitochondria have quietly become the new frontier of longevity science. These cellular powerhouses (once confined to biology labs) are now the mainstay of a growing movement that values personalized health metrics over generic wellness advice. Now, serious biohackers and concerned citizens alike aren't just counting steps, they're tracking cellular efficiency.
This rise in mitochondrial testing reflects a deeper cultural shift: aging is increasingly defined not by wrinkles or birthdays, but by the performance of our cells. Personalized data is transforming that narrative, giving us the tools to measure, monitor, and optimize our biology in real-time.
Mitochondrial health is fast becoming a top-tier biomarker for biological age, and testing is no longer limited to elite circles.
ATP output reveals how effectively your mitochondria convert fuel into usable energy, while oxidative stress metrics track how well your cells are managing harmful free radicals. Some labs now offer a full ATP Profile, which differentiates between mitochondrial and glycolytic energy production.
Consumer-facing tests from companies like Tally Health, Novos, and InsideTracker give users unprecedented access to mitochondrial metrics. These diagnostic tools signal a broader trend: personalized data is now the baseline, not the luxury. As precision wellness company 10X Health explains, 'Advancements in testing technology, reductions in lab costs, and better access to health data have made it possible to bring this kind of precision-based approach to a much wider population.'
More and more research shows that when your mitochondria aren't working well, it doesn't just happen with age; it causes aging. One study found that the buildup of harmful molecules called ROS (reactive oxygen species) is linked to nearly every major age-related health issue, from heart disease and muscle loss to memory decline and diabetes.
Another study found that a compound called PQQ can help your body grow new, healthier mitochondria and burn fat more efficiently. Other research has tied mitochondrial damage directly to brain diseases like Alzheimer's and Parkinson's, showing that when your cells can't make energy properly, the effects show up all over your body, especially in how you age.
The takeaway: Poor mitochondrial performance isn't a side effect of aging; it's the main character.
Modern mitochondrial testing can reveal far more than fatigue levels — it paints a picture of how well your cells are functioning and aging.
Tally Health assesses biological age through a cheek swab and delivers personalized lifestyle and supplement recommendations. Users receive insights into energy metabolism, inflammation, and epigenetic aging.
Novos offers epigenetic testing along with a two-part supplement system: Novos Core and Novos Boost. The formulas combine ingredients like Pterostilbene, Glycine, and NMN to support mitochondrial health and cellular longevity.
InsideTracker analyzes key blood biomarkers (like glucose, lipid levels, and inflammation markers) to provide a customized biological age score and science-backed interventions.
These tools don't just give you a number; they uncover what's driving that number and offer personalized, research-based strategies to reverse course.
Once mitochondrial inefficiencies are identified, there are concrete ways to restore function and resilience.
Even small, targeted changes (like improving sleep hygiene, tweaking workout protocols, or adjusting your supplement stack) can have an outsized effect when guided by precise data.
Personalized health optimization has long been the domain of athletes and high performers, but that's changing. The integration of low-cost, high-accuracy diagnostics into mainstream wellness is redefining how we approach aging.
Mitochondrial health testing stands at the forefront of that shift. It turns the invisible drivers of fatigue, inflammation, and decline into tangible metrics, and most importantly, into treatable targets.
In an era overwhelmed by generic health advice and trendy biohacks, mitochondrial testing offers something more grounded: measurable biology and personalized insights.
Click here to learn more about 10x Health

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

6 hours ago

Diabetes drug may cut migraine days in half with little weight loss: Study

Drugs in the same family as Ozempic and Wegovy are known for treating diabetes and helping with weight loss, but a small, early-stage study suggested they might also ease migraines -- even when there's no weight loss. The benefit appears to come from lowering pressure in the brain, Dr. Simone Braca, a neurologist at the University of Naples Federico II and lead author of the study, explained to ABC News. 'This study is very interesting in that the GLP 1s are hypothesized to lower brain pressure, which can then lower your chance of getting a headache or a migraine,' Braca said. The small, 12-week study tracked 26 adults with obesity who had chronic or frequent migraines. Published in Headache -- the official journal of the American Headache Society -- and presented at this week's European Academy of Neurology meeting in Finland, it tested liraglutide, a type of GLP-1 drug commonly used for diabetes and weight loss. After taking a daily 1.8 mg dose of liraglutide for three months -- the amount typically used to treat diabetes -- their average number of headache days per month dropped from 20 to about nine. Participants also reported less disability from migraines, with scores on a standard headache impact scale cut by more than half. Although some participants lost a small amount of weight, Braca said the few lost pounds were not meaningful enough to explain the improvement in migraines. Instead, Braca pointed to pressure from cerebrospinal fluid -- the liquid that surrounds and cushions the brain and spine. He said he believes that even slight buildups of this fluid can press on nearby veins and nerves in the brain, potentially triggering migraines. 'An increased pressure of the spinal fluid in the brain may be one of the mechanisms underlying migraine,' Braca said. 'And if we target this mechanism, this preliminary evidence suggests that it may be helpful for migraine.' Nearly half of patients reported at least a 50% reduction in headache days, according to the Headache paper. About 40% experienced mild side effects like nausea or constipation. None stopped taking the medication. With such promising results, Braca and his research team, led by Dr. Roberto De Simone, are already planning larger trials. Future studies will measure brain pressure more directly and explore whether other GLP 1 drugs might also offer the same relief but with fewer side effects. 'There are still a substantial portion of migraine patients that face an unmet need and that live with its burden,' he said. 'New drugs that could target other pathways, I think that could be reassuring to those patients and give them hope.' The study adds to growing evidence that GLP-1 drugs may have benefits beyond diabetes and weight loss. Researchers are already studying these medications for a range of other conditions, including reducing the risk of heart disease and stroke, easing symptoms of addiction and treating Alzheimer's disease.

Fox News

a day ago

• Fox News

Bill Gates reveals 'next phase of Alzheimer's fight' as he shares dad's personal battle

Bill Gates is speaking out about his personal experience with Alzheimer's — and his hope for progress in fighting the disease. In an essay published this week on his blog at the Microsoft co-founder and tech billionaire, 69, reflected on the difficulty of spending another Father's Day without his dad, Bill Gates Sr. The elder Gates passed away in 2020 at the age of 94 after battling Alzheimer's. "It was a brutal experience, watching my brilliant, loving father go downhill and disappear," Gates wrote in the blog post. Today, motivated by his own experience with the common dementia, Gates — who serves as chair of the Gates Foundation — is committed to working toward a cure for the common dementia, which currently affects more than seven million Americans, or one in nine people over 65. In his blog, Gates expressed optimism about the "massive progress" being made in the fight against Alzheimer's and other dementias. Last year, Gates said he visited Indiana University's School of Medicine in Indianapolis to tour the labs where teams have been researching Alzheimer's biomarkers. "I also got the opportunity to look under the hood of new automated machines that will soon be running diagnostics around the world," he wrote. "It's an exciting time in a challenging space." One of the biggest breakthroughs in Alzheimer's research, according to Gates, is blood-based diagnostic tests, which detect the ratio of amyloid plaques in the brain. (Amyloid plaques, clumps of protein that accumulate in the brain, are one of the hallmarks of Alzheimer's.) "I'm optimistic that these tests will be a game-changer," Gates wrote. Last month, the U.S. Food and Drug Administration (FDA) approved the first blood-based test for patients 55 years and older, as Fox News Digital reported at the time. "A simple, accurate and easy-to-run blood test might one day make routine screening possible." Traditionally, Gates noted, the primary path to Alzheimer's diagnosis was either a PET scan (medical imaging) or spinal tap (lumbar puncture), which were usually only performed when symptoms emerged. The hope is that blood-based tests could do a better job of catching the disease early, decline begins. "We now know that the disease begins 15 to 20 years before you start to see any signs," Gates wrote. "A simple, accurate and easy-to-run blood test might one day make routine screening possible, identifying patients long before they experience cognitive decline," he stated. Gates said he is often asked, "What is the point of getting diagnosed if I can't do anything about it?" To that end, he expressed his optimism for the future of Alzheimer's treatments, noting that two drugs — Lecanemab (Leqembi) and Donanemab (Kisunla) — have gained FDA approval. "Both have proven to modestly slow down the progression of the disease, but what I'm really excited about is their potential when paired with an early diagnostic," Gates noted. He said he is also hopeful that the blood tests will help speed up the process of enrolling patients in clinical trials for new Alzheimer's drugs. To accomplish this, Gates is calling for increased funding for research, which often comes from federal grants. "This is the moment to spend more money on research, not less," he wrote, also stating that "the quest to stop Alzheimer's has never had more momentum." "There is still a huge amount of work to be done — like deepening our understanding of the disease's pathology and developing even better diagnostics," Gates went on. "I am blown away by how much we have learned about Alzheimer's over the last couple of years." Gates pointed out that when his father had Alzheimer's, it was considered a "death sentence," but that is starting to change. "I am blown away by how much we have learned about Alzheimer's over the last couple of years," he wrote. For more Health articles, visit "I cannot help but be filled with a sense of hope when I think of all the progress being made on Alzheimer's, even with so many challenges happening around the world. We are closer than ever before to a world where no one has to watch someone they love suffer from this awful disease."

Yahoo

2 days ago

• Yahoo

Dad, 41, Diagnosed with Alzheimer's: 'You Feel Guilty That You're Doing That to the Kids'

Fraser, a 41-year-old dad, opened up about his experience with early-onset Alzheimer's after being diagnosed with the disease in 2024 On a YouTube channel, he tracks the symptoms that he experiences and how the illness is impacting his family 'You feel guilty that you're doing that to the kids,' he admitted, 'even though it's not your fault'A father with early-onset Alzheimer's disease is sharing how his symptoms began manifesting before his diagnosis — and when his family noticed something was wrong. Fraser, a researcher from Australia, shares an honest look at his journey on his YouTube channel — I (don't) have dementia. The symptoms, he explained, began nearly two and a half years before his diagnosis in 2024. 'I remember I was having some pretty big memory flaws,' Fraser, 41, said in a video, sharing that one incident came when he sat down to watch a movie with his partner, who told him, ''We watched that, like, a month ago.' " He continued, recalling, "Anyway I watched the whole movie and the ending was still a complete surprise — I had no memory of watching it, whatsoever.' Another time, the dad to teenage girls shared that one daughter told him she was going to the movies with friends and would be out late. 'It came to nighttime and I started freaking out thinking, 'Where's my daughter?' Like, I was genuinely freaking out,' Fraser said. Obviously, his kids noticed; he explained in another video: 'I asked my kids, just sort of casually, and they said, like, 'Everyone has memory issues that they have, they forget stuff in everyday life … we just noticed that you were just doing them more often, more frequently.' ' He shared that these days, he writes everything down in a diary as he struggles through 'every day scheduling,' explaining that if plans change, he can recall the original plan but not the revision. Alzheimer's, the most commonly diagnosed form of dementia, is generally diagnosed in older adults, according to John Hopkins Medicine. Treatment can help slow the progression of the disease, but it's not known why some people, like Fraser, develop it early. The ebb and flow of the symptoms, Fraser said in a recent video, can make you 'certain you have it and certain you do not have it.' 'It will change your identity,' he admitted, confessing that he can be 'selfish' and 'not follow through with [his] word.' Fraser shared that when he's in later stages, 'I can largely be off with the fairies, thinking I'm hanging out with my kid friend in primary school.' He said he'd rather his loved ones 'just [go] along with it as opposed to trying to correct me all the time.' Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. But the hardest part, he added, is knowing how it's impacting his children. 'They're already having to make accommodations,' Fraser said in a video while on a retreat with other people who've been diagnosed with early-onset Alzheimer's. 'Being the parent, who's the one who's supposed to be supportive and the one who's supposed to be there for the kids … that whole issue of that sort of feeling like it's flipping a little bit.' 'You feel guilty that you're doing that to the kids,' he said, 'even though it's not your fault.' Read the original article on People